US2005147688A1PendingUtilityA1

Method for the delivery of a biologically active agent

Priority: Mar 11, 2002Filed: Feb 11, 2005Published: Jul 7, 2005
Est. expiryMar 11, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61K 9/006A61K 9/0056A61K 9/1075A61K 9/10
28
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product.

Claims

exact text as granted — not AI-modified
1 . A method for administration of a microfluidized nanosuspension containing a biologically active agent to a subject comprising: 
 forming, via a microfluidization process, a stable nanosuspension comprising nanodroplets of at least one biologically active agent; and    administering said nanosuspension to said subject;    wherein said biologically active agent is absorbed into the bloodstream of said subject.    
     
     
         2 . The method of  claim 1 , wherein said subject is a human.  
     
     
         3 . The method of  claim 1 , wherein said subject is an animal.  
     
     
         4 . The method of  claim 1 , wherein said nanosuspension contains particles in a size range of about 87 nm to about 10 μm.  
     
     
         5 . The method of  claim 1 , wherein said nanosuspension further includes a permeation enhancer.  
     
     
         6 . The method of  claim 1 , wherein said biologically active agent is at least one nutritional product.  
     
     
         7 . The method of  claim 1 , wherein said biologically active agent is a pharmaceutical.  
     
     
         8 . The method of  claim 1 , wherein said method of administration is at least one method selected from the group consisting of parenteral, intrathecal, intravenous, transdermal, transmucosal, or combinations thereof.  
     
     
         9 . The method of  claim 1 , wherein said nanosuspension is in the form of a microfluidized spray, an aerosol, a tablet, a capsule, a pill, a liquid, a suppository, or a gel.

Join the waitlist — get patent alerts

Track US2005147688A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.